A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
about
Recipients of vaccine against the 1976 "swine flu" have enhanced neutralization responses to the 2009 novel H1N1 influenza virusInfluenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferretsAvian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetThe kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus.Construction and Immunogenicity Evaluation of Recombinant Influenza A Viruses Containing Chimeric Hemagglutinin Genes Derived from Genetically Divergent Influenza A H1N1 Subtype Viruses.Prospects for developing an effective particle-mediated DNA vaccine against influenza.Response of BALB/c mice to a monovalent influenza A (H1N1) 2009 split vaccine.Several hemagglutinins of same serotype for induction of broad immunity against influenza A virus antigenic drift variants: WO2008048984.Glycan shielding of the influenza virus hemagglutinin contributes to immunopathology in mice.Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complicationsInactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections.Contribution of murine innate serum inhibitors toward interference within influenza virus immune assays.Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.Immunogenicity and clinical protection against equine influenza by DNA vaccination of ponies.Vitamin Supplementation at the Time of Immunization with a Cold-Adapted Influenza Virus Vaccine Corrects Poor Mucosal Antibody Responses in Mice Deficient for Vitamins A and DOral Modeling of an Adenovirus-Based Quadrivalent Influenza Vaccine in Ferrets and Mice.Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice.Correlates of vaccine protection from influenza and its complications.Positive Contribution of Adjuvanted Influenza Vaccines to the Resolution of Bacterial Superinfections.Live attenuated influenza virus increases pneumococcal translocation and persistence within the middle ear.Live attenuated influenza vaccine, but not pneumococcal conjugate vaccine, protects against increased density and duration of pneumococcal carriage after influenza infection in pneumococcal colonized mice.Enhanced CD103 Expression and Reduced Frequencies of Virus-Specific CD8+ T Cells Among Airway Lymphocytes After Influenza Vaccination of Mice Deficient in Vitamins A + D.EDiP: the Epitope Dilution Phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens.A Review of DNA Vaccines Against InfluenzaThe Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection
P2860
Q24600337-E38EC205-125D-4BC6-975B-E12DF48B7538Q28742787-2CCD7EA7-821D-40E2-9E31-BFAB481AA3CFQ30227194-8C18EF55-1FD3-4491-9BF1-9AFD27C044C9Q30354732-3E348A6A-E5BA-4937-BA72-181CF83DC5ACQ30375514-70EBF372-8694-4311-A316-469B77521778Q30380300-08404284-667F-4932-8F5C-3D9F8ADC9DFDQ30385138-D8E7AD86-A050-4B1D-8611-D6E035958B0FQ30385956-67999CBE-F75C-4DF2-B85D-1386515F6FEFQ30394731-3D0AC888-5A16-481A-8ABB-C44C1E17D531Q30412222-B465015B-13BE-4436-A793-FE1A58F2598DQ30586381-30E3FBE2-E585-4170-86A0-3657520E8970Q33725040-C442D644-93B5-409F-8180-25CB9B44CF11Q33769373-3458D337-5C17-4D72-92F6-C5857C8B05ADQ34885060-37483B4D-99B5-4370-9D6F-507BAD5D3514Q35605808-7FBC8EF7-35A2-45AF-AB65-D85F64CF197FQ35887453-0AF836D4-CB43-407B-B5D8-E34B0FDF6C83Q36327122-64E0CCAB-528B-434A-AA18-22AEC237CB37Q36665642-48696C53-72A5-48D2-9603-925CF344B77BQ37056528-5451EA28-136C-48AB-B71B-A048693B674FQ37621640-461F1CBE-0605-463A-85E8-AF6F43CE433BQ37976539-BBFFC839-4CC3-4660-8919-E2C2CBF870BDQ40779990-47AA5F3F-FAA5-4637-BDFC-EB63BBD07246Q41600044-36C8F1A7-9862-49DF-9B65-0DED365286C7Q42255202-87E15D85-B810-422C-B877-65C18111E72BQ45324924-F5831626-4762-4589-9316-F8683A92383CQ47311278-279D3FD7-F0CE-4574-8EFF-5072F72639E4Q57094261-70DC7E46-99A6-422F-B7B2-8BF79D26F1BFQ58783155-066882E1-257F-4CEB-BB5C-E077216B706B
P2860
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@en
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@nl
type
label
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@en
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@nl
prefLabel
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@en
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype.
@nl
P2860
P1433
P1476
A multi-valent vaccine approach that elicits broad immunity within an influenza subtype
@en
P2093
Victor C Huber
P2860
P304
P356
10.1016/J.VACCINE.2008.12.023
P407
P577
2009-01-07T00:00:00Z